Cao Mingjing, Chen Chunying
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, China.
University of Chinese Academy of Sciences, China.
Natl Sci Rev. 2022 Jun 17;9(10):nwac119. doi: 10.1093/nsr/nwac119. eCollection 2022 Oct.
Instead of the nanostructure and biological activity, this perspective highlights the metabolic processes from biotransformation to bioavailability, to bridge the gap between the cradle (structure design) and endpoint (efficacy and/or safety) of nanomedicines.
与纳米结构和生物活性不同，此观点强调了从生物转化到生物利用度的代谢过程，以弥合纳米药物的起点（结构设计）和终点（疗效和/或安全性）之间的差距。
